Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

FRANKFURT AM MAIN, Germany — Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics. Read MoreRead More